Role of GnRH Agonists in Frozen Embryo Transfer

Introduction to GnRH Agonist Therapy

The American Society of Clinical Oncology (ASCO) guidelines from 2013 state that in the context of fertility preservation for female cancer patients, ovarian suppression with GnRH agonists should not be used as a fertility preservation method due to insufficient evidence 2
The National Comprehensive Cancer Network (NCCN) suggests that GnRH agonists may be beneficial in the context of fertility preservation for cancer patients, although the evidence is limited by small sample sizes and lack of blinding 1

The use of GnRH agonists in patients with adenomyosis may improve implantation and pregnancy rates, although the evidence is not strong enough to support routine use in all patients 1
For patients with repeated implantation failures, GnRH agonists may show a trend towards improvement, but the evidence is weak and not statistically significant 2

A 5-year follow-up analysis found that GnRH agonist administration does not significantly impact premature ovarian failure or future pregnancy rates, according to the National Comprehensive Cancer Network (NCCN) 1